MYCO Stock Overview
Mydecine Innovations Group Inc., a biotechnology company, engages in the development and commercialization of psilocybin products for treating mental health problems.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 2/6 |
Dividends | 0/6 |
Mydecine Innovations Group Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$0.015 |
52 Week High | US$0.70 |
52 Week Low | US$0.01 |
Beta | 3.2 |
1 Month Change | -25.00% |
3 Month Change | 0% |
1 Year Change | -97.79% |
3 Year Change | -99.93% |
5 Year Change | -99.97% |
Change since IPO | -99.99% |
Recent News & Updates
Recent updates
Shareholder Returns
MYCO | CA Pharmaceuticals | CA Market | |
---|---|---|---|
7D | -25.0% | -3.6% | -2.1% |
1Y | -97.8% | 58.0% | 3.6% |
Return vs Industry: MYCO underperformed the Canadian Pharmaceuticals industry which returned 46% over the past year.
Return vs Market: MYCO underperformed the Canadian Market which returned 3.2% over the past year.
Price Volatility
MYCO volatility | |
---|---|
MYCO Average Weekly Movement | 47.5% |
Pharmaceuticals Industry Average Movement | 14.2% |
Market Average Movement | 9.2% |
10% most volatile stocks in CA Market | 18.4% |
10% least volatile stocks in CA Market | 3.1% |
Stable Share Price: MYCO's share price has been volatile over the past 3 months.
Volatility Over Time: MYCO's weekly volatility has increased from 33% to 48% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2013 | 3 | Josh Bartch | www.mydecine.com |
Mydecine Innovations Group Inc., a biotechnology company, engages in the development and commercialization of psilocybin products for treating mental health problems. The company primarily focuses on treating smoking cessation. Its lead product drug candidates include MYCO-001, MYCO-002, MYCO003, and MYCO-004.
Mydecine Innovations Group Inc. Fundamentals Summary
MYCO fundamental statistics | |
---|---|
Market cap | CA$906.98k |
Earnings (TTM) | -CA$18.07m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs MYCO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
MYCO income statement (TTM) | |
---|---|
Revenue | CA$0 |
Cost of Revenue | CA$0 |
Gross Profit | CA$0 |
Other Expenses | CA$18.07m |
Earnings | -CA$18.07m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.29 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | -84.4% |
How did MYCO perform over the long term?
See historical performance and comparison